ExThera Blood-Infection Filter Will Get 'Expedited Access' From US FDA
Executive Summary
The firm's Seraph 100 blood filter leverages proprietary receptor technology to capture and remove drug-resistant infections and return the blood to the patient with cells intact. FDA says it's a novel enough approach to infections suffered by dialysis patients to be accepted into the Expedited Access Pathway.
You may also be interested in...
Blood Filter Start-Up ExThera Gets Fresenius Backing
New investor Fresenius Medical Care Ventures GmbH is leading a Series B financing round in ExThera Medical to help fund clinical trials in Germany and the US of the latter’s Seraph Microbind affinity blood filter.
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
Device Week, March 8, 2019 – Scott Gottlieb Resigns
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?